Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
NCT02695472 is registered in ClinicalTrials.gov with Neuralstem Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
- Lead sponsor
- Neuralstem Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2016
- Completion date
- December 31, 2017
- Enrollment
- 220 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.